Literature DB >> 9729514

Neutral endopeptidase inhibition potentiates the natriuretic actions of adrenomedullin.

O Lisy1, M Jougasaki, J A Schirger, H H Chen, P T Barclay, J C Burnett.   

Abstract

Adrenomedullin (ADM) is a potent renal vasodilating and natriuretic peptide possessing a six amino acid disulfide ring. Neutral endopeptidase 24.11 (NEP) is localized in greatest abundance in the kidney and cleaves endogenous peptides like atrial natriuretic peptide, which also possesses a disulfide ring. We hypothesized that NEP inhibition potentiates the natriuretic actions of exogenous ADM in anesthetized dogs (n = 6). We therefore investigated renal function in which one kidney received intrarenal infusion of ADM (1 ng . kg-1 . min-1) while the contralateral kidney served as control before and during the systemic infusion of a NEP inhibitor (Candoxatrilat, 8 microg . kg-1 . min-1; Pfizer). In response to ADM, glomerular filtration rate (GFR) in the ADM kidney did not change, whereas renal blood flow, urine flow (UV), and urinary sodium excretion (UNaV) increased from baseline. Proximal and distal fractional reabsorption of sodium decreased in the ADM-infused kidney. In response to systemic NEP inhibition, UNaV and UV increased further in the ADM kidney. Indeed, DeltaUNaV and DeltaUV were markedly greater in the ADM kidney compared with the control kidney. Plasma ADM was unchanged during ADM infusion but increased during NEP inhibition. In conclusion, the present investigation is the first to demonstrate that NEP inhibition potentiates the natriuretic and diuretic responses to intrarenal ADM. This potentiation occurs secondary to a decrease in tubular sodium reabsorption. Lastly, the increase in plasma ADM during systemic NEP inhibition supports the conclusion that ADM is a substrate for NEP.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9729514     DOI: 10.1152/ajprenal.1998.275.3.F410

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  17 in total

Review 1.  Neprilysin Inhibition as a PARADIGM Shift in Heart Failure Therapy.

Authors:  Ruth Hsiao; Barry Greenberg
Journal:  Curr Heart Fail Rep       Date:  2016-08

Review 2.  Effects of omapatrilat on pharmacodynamic biomarkers of neutral endopeptidase and Angiotensin-converting enzyme activity in humans.

Authors:  O Vesterqvist; R A Reeves
Journal:  Curr Hypertens Rep       Date:  2001-12       Impact factor: 5.369

Review 3.  Role of the natriuretic peptides in the cardiorenal and humoral actions of omapatrilat: insights from experimental heart failure.

Authors:  H H Chen; A Cataliotti; J C Burnett
Journal:  Curr Hypertens Rep       Date:  2001-12       Impact factor: 5.369

Review 4.  Novel neurohumoral factors in congestive heart failure: adrenomedullin.

Authors:  J G Lainchbury
Journal:  Curr Cardiol Rep       Date:  2001-05       Impact factor: 2.931

Review 5.  Long-term neprilysin inhibition - implications for ARNIs.

Authors:  Duncan J Campbell
Journal:  Nat Rev Cardiol       Date:  2016-12-15       Impact factor: 32.419

6.  The Role of Neprilysin Inhibitors in Cardiovascular Disease.

Authors:  Jared Mills; Orly Vardeny
Journal:  Curr Heart Fail Rep       Date:  2015-12

7.  Effects of adrenomedullin on angiotensin II stimulated atrial natriuretic peptide and arginine vasopressin secretion in healthy humans.

Authors:  M C Petrie; J E McDonald; C Hillier; J J Morton; J J McMurray
Journal:  Br J Clin Pharmacol       Date:  2001-08       Impact factor: 4.335

8.  Adrenomedullin (ADM) in the human forearm vascular bed: effect of neutral endopeptidase inhibition and comparison with proadrenomedullin NH2-terminal 20 peptide (PAMP).

Authors:  I B Wilkinson; C M McEniery; K H Bongaerts; H MacCallum; D J Webb; J R Cockcroft
Journal:  Br J Clin Pharmacol       Date:  2001-08       Impact factor: 4.335

9.  The neurohormonal basis of pulmonary hypertension in heart failure with preserved ejection fraction.

Authors:  Masaru Obokata; Garvan C Kane; Yogesh N V Reddy; Vojtech Melenovsky; Thomas P Olson; Petr Jarolim; Barry A Borlaug
Journal:  Eur Heart J       Date:  2019-12-01       Impact factor: 29.983

Review 10.  Combined Angiotensin Receptor Antagonism and Neprilysin Inhibition.

Authors:  Scott A Hubers; Nancy J Brown
Journal:  Circulation       Date:  2016-03-15       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.